safety, and efficacy in the first year of clinical practice. *Stroke* 1998;29:18–22.

19. Kase CS, Pessin MS, Zivin JA, et al. Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. *Am J Med* 1992;92:384–390.
20. Sloan MA, Sila CA, Mahaffey KW, et al. Clinical and radiographic factors associated with mortality following intracranial hemorrhage after thrombolysis for acute myocardial infarction. *Stroke* 1996;27:183. Abstract.
21. Gebel JM, Sila CA, Sloan MA, et al. Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. *Stroke* 1998;29:563–569.
22. Fisher CM, Adams RD. Observations on brain embolism with special reference to the mechanism of hemorrhagic infarction. *J Neuropathol Exp Neurol* 1951;10:92–93.
23. Lyden PD, Grotta JC, Levine SR, Marler JR, Frankel MR, Brott TG. Intravenous thrombolysis for acute stroke. *Neurology* 1997;49:14–29.
24. Ogata J, Yutani C, Imakita M, et al. Hemorrhagic infarct of the brain without a reopening of the occluded arteries in cardioembolic stroke. *Stroke* 1989;20:876–883.
25. Trouillas P, Nighoghossian N, Derex L, et al. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid

territory stroke: determination of etiological, topographic, and radiological outcome factors. *Stroke* 1998;29:2529–2540.

26. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke: potential contributing factors in the European Cooperative Acute Stroke Study. *Stroke* 1997;28:957–960.
27. Jaillard A, Cornu C, Durieux A, et al. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. *Stroke* 1999;30:1326–1332.
28. Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycemia an independent predictor of poor outcome after acute stroke? results of a long term follow up study. *BMJ* 1997;314:1303–1306.
29. Dietrich WD, Alonso O, Busto R. Moderate hyperglycemia worsens acute blood-brain barrier injury after forebrain ischemia in rats. *Stroke* 1993;24:111–116.
30. de Courten-Myers GM, Kleinholtz M, Holm P, et al. Hemorrhagic infarct conversion in experimental stroke. *Ann Emerg Med* 1992;21:120–126.
31. Kawai N, Keep RF, Betz AL. Hyperglycemia and the vascular effects of cerebral ischemia. *Stroke* 1997;28:149–154.
32. Kalimo H, Rehnström S, Soderfeldt B, Olsson Y, Siesjö BK. Brain lactic acidosis and ischemic cell damage, 2: histopathology. *J Cereb Blood Flow Metab* 1981;1:313–327.

NeuroImages

Figure. (A) Axial T2-weighted images show a large right occipitoparietal lesion with alternating concentric hyperintense and isointense rings. There is a small oval lesion on the left. (B) Axial T1-weighted images after administration of gadolinium-DTPA show marked and synchronous contrast enhancement of the hyperintense rings seen on the T2-weighted images.

Balo's concentric sclerosis demonstrated by contrast MRI

O. Kastrup, MD, P. Stude, MD, V. Limmroth, MD, Essen, Germany

We report a 43-year-old man with Balo's concentric sclerosis. Clinically, he had recurring episodes of memory deficits and right-sided hemiparesis. MRI after application of gadolinium showed alternating bands of enhancement and rings of lack of enhancement corresponding with the rings of preserved myelin.¹ There was synchronous enhancement

of all lamellae (figure). CSF examination was abnormal, with mildly elevated cells (29/mm³) and protein (56 mg/dL), but there was no intrathecal IgG synthesis or oligoclonal bands. The relationship of Balo's concentric sclerosis to MS continues to be unclear.²

1. Chen, CJ, Ro LS, Wang LJ, Wong YC. Balo's concentric sclerosis: MRI. *Neuroradiology* 1996;38:322–324.
2. Terseoglu MM, Reich DR. Balo's concentric sclerosis: a rare form of multiple sclerosis manifested as a dominant cerebral mass without other white matter lesions on MR. *AJR Am J Roentgenol* 1993;160:901. Letter.

Neurology®

Balo's concentric sclerosis demonstrated by contrast MRI

O. Kastrup, P. Stude and V. Limmroth

Neurology 2001;57;1610

DOI 10.1212/WNL.57.9.1610

This information is current as of November 13, 2001

Updated Information & Services	including high resolution figures, can be found at: http://n.neurology.org/content/57/9/1610.full
References	This article cites 2 articles, 0 of which you can access for free at: http://n.neurology.org/content/57/9/1610.full#ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): All Demyelinating disease (CNS) http://n.neurology.org/cgi/collection/all_demyelinating_disease_cns MRI http://n.neurology.org/cgi/collection/mri Multiple sclerosis http://n.neurology.org/cgi/collection/multiple_sclerosis
Permissions & Licensing	Information about reproducing this article in parts (figures,tables) or in its entirety can be found online at: http://www.neurology.org/about/about_the_journal#permissions
Reprints	Information about ordering reprints can be found online: http://n.neurology.org/subscribers/advertise

Neurology® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.